QR-koodi

Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes

Abstract Rhabdomyosarcomas (RMS) are mesenchyme‐derived tumors and the most common childhood soft tissue sarcomas. Treatment is intense, with a nevertheless poor prognosis for high‐risk patients. Discovery of new therapies would benefit from additional preclinical models. Here, we describe the gener...

Täydet tiedot

Tallennettuna:
Päätekijät: Michael T Meister, Marian J A Groot Koerkamp, Terezinha de Souza, Willemijn B Breunis, Ewa Frazer‐Mendelewska, Mariël Brok, Jeff DeMartino, Freek Manders, Camilla Calandrini, Hinri H D Kerstens, Alex Janse, M Emmy M Dolman, Selma Eising, Karin P S Langenberg, Marc van Tuil, Rutger R G Knops, Sheila Terwisscha van Scheltinga, Laura S Hiemcke‐Jiwa, Uta Flucke, Johannes H M Merks, Max M van Noesel, Bastiaan B J Tops, Jayne Y Hehir‐Kwa, Patrick Kemmeren, Jan J Molenaar, Marc van de Wetering, Ruben van Boxtel, Jarno Drost, Frank C P Holstege
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer Nature 2022-08-01
Sarja:EMBO Molecular Medicine
Aiheet:
rhabdomyosarcoma
mesenchymal
tumoroid
drug screening
CRISPR/Cas9
Linkit:https://doi.org/10.15252/emmm.202216001
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia